Literature DB >> 26813747

Mismatch Repair Protein Expression in Clear Cell Carcinoma of the Ovary: Incidence and Morphologic Associations in 109 Cases.

Jennifer A Bennett1, Vicente Morales-Oyarvide, Sharon Campbell, Teri A Longacre, Esther Oliva.   

Abstract

Several morphologic features have been reported to be predictive of abnormal expression of mismatch repair (MMR) proteins in endometrial and colon carcinomas. Although it is known that abnormal MMR expression is increased in frequency in ovarian endometrioid and clear cell carcinomas, no such histologic correlation has been identified. We reviewed 109 unselected ovarian clear cell carcinomas for specific tumor characteristics (architecture, nuclear atypia, signet ring cells, stromal hyalinization, background precursor) and inflammatory response (peritumoral lymphocytes found along the leading edge of the tumor, intratumoral stromal inflammation found within the tumor, percentage of plasma cells in the intratumoral stromal inflammation, tumor-infiltrating lymphocytes) and performed immunohistochemistry for all 4 MMR proteins. Abnormal MMR expression was identified in 6% of tumors and included MSH2/MSH6 (3), MLH1/PMS2 (1), MSH6 (1), and PMS2 (1). These patients had a mean age of 40 (range, 31 to 48) years, which contrasted with a mean of 53.2 (range, 28 to 82) years for the overall cohort. One had a concurrent diagnosis of endometrial carcinoma, whereas another had a family history of endometrial carcinoma. None had a personal/family history of colonic carcinoma. Tumors with diffuse intratumoral stromal inflammation and peritumoral lymphocytes were more frequently associated with MMR loss on univariate analysis (P<0.001 and 0.047, respectively) with diffuse intratumoral stromal inflammation remaining a significant independent predictor on multivariate analysis. None of the other morphologic features evaluated reached statistical significance. Although previous series have been unable to identify a relationship between histology and MMR expression, this study identified a correlation with diffuse intratumoral stromal inflammation and peritumoral lymphocytes, 2 features that potentially could be selected for MMR analysis if corroborated by other studies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26813747     DOI: 10.1097/PAS.0000000000000602

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

1.  Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.

Authors:  Brian C Willis; Emily A Sloan; Kristen A Atkins; Mark H Stoler; Anne M Mills
Journal:  Mod Pathol       Date:  2017-07-28       Impact factor: 7.842

2.  The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.

Authors:  Hiroko Matsuura; Morikazu Miyamoto; Taira Hada; Hiroki Ishibashi; Hideki Iwahashi; Soichiro Kakimoto; Rie Suzuki; Tsubasa Ito; Jin Suminokura; Hitoshi Tsuda; Masashi Takano
Journal:  Arch Gynecol Obstet       Date:  2022-05-04       Impact factor: 2.344

Review 3.  Magnetic resonance imaging findings of cystic ovarian tumors: major differential diagnoses in five types frequently encountered in daily clinical practice.

Authors:  Ayumi Ohya; Yasunari Fujinaga
Journal:  Jpn J Radiol       Date:  2022-08-02       Impact factor: 2.701

4.  The frequency and clinical implication of mismatch repair protein deficiency in Chinese patients with ovarian clear cell carcinoma.

Authors:  Shuang Ye; Shuling Zhou; Siyuan Zhong; Boer Shan; Wenhua Jiang; Wentao Yang; Xu Cai; Huijuan Yang
Journal:  BMC Cancer       Date:  2022-04-23       Impact factor: 4.638

5.  Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.

Authors:  Naoki Kawahara; Kenji Ogawa; Mika Nagayasu; Mai Kimura; Yoshikazu Sasaki; Hiroshi Kobayashi
Journal:  Biomed Rep       Date:  2017-09-27

6.  Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.

Authors:  Rachel Hodan; Kerry Kingham; Kristina Cotter; Ann K Folkins; Allison W Kurian; James M Ford; Teri Longacre
Journal:  Cancer Med       Date:  2020-12-25       Impact factor: 4.452

7.  Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma.

Authors:  Hangqi Liu; Zhiwen Zhang; Longyun Chen; Junyi Pang; Huanwen Wu; Zhiyong Liang
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

8.  The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.

Authors:  Amit Atwal; Tristan Snowsill; Marcus Cabrera Dandy; Thomas Krum; Claire Newton; Dafydd Gareth Evans; Emma J Crosbie; Neil A J Ryan
Journal:  Int J Cancer       Date:  2022-07-06       Impact factor: 7.316

Review 9.  The Evolution of Ovarian Carcinoma Subclassification.

Authors:  Martin Köbel; Eun Young Kang
Journal:  Cancers (Basel)       Date:  2022-01-14       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.